Analyst Matthew O'Brien reaffirms an Overweight rating and $420 price target for Stryker, highlighting the potential of its new Mako RPS handheld orthopedic robot to capture cost-sensitive markets and compete with rivals like Zimmer Biomet.
DexCom Inc. (DXCM) has released preliminary Q4 figures that exceeded expectations and provided robust long-term guidance, reinforcing its position as a favored pick among analysts and hedge funds in the medical devices sector.
A recent physician survey on renal denervation procedure volumes has prompted analysts to adopt a more measured view of Medtronic's near-term growth potential, even as the medical device giant remains a favored long-term holding.
Novo Nordisk charts a bold new course, launching a pivotal oral obesity drug while restructuring its workforce and deepening its investment in next-generation cell therapies for metabolic diseases.
Doctors Without Borders (MSF) has definitively rejected an Israeli order to hand over sensitive staff information, following months of failed negotiations. The move comes amid a wider crackdown on aid groups and a devastating toll on healthcare workers in the conflict.
CLEAR Secure, the biometric identity company known for its airport expedited lanes, is deepening its ties to core government systems. CEO Caryn Seidman Becker's appointment to the Federal Reserve Bank of New York's board and a new contract with the Centers for Medicare & Medicaid Services signal a strategic push into financial and public health infrastructure.
The medical aid group Médecins Sans Frontières (MSF) has refused to comply with an Israeli order to hand over detailed staff lists as a condition for continuing its work in Gaza and the West Bank, warning the demand jeopardizes the safety of its personnel and could cripple humanitarian operations.
Medtronic secures a key European regulatory nod for its latest pulsed field ablation catheter while deepening its collaboration with Mindray, signaling a strategic push into high-growth areas of cardiac care and ambulatory surgery.
A campaign-trail proposal to temporarily cap credit card interest at 10% could offer significant savings for millions of borrowers, but experts warn of potential unintended consequences for credit access and long-term financial health.
In a landmark deal, AstraZeneca has licensed a suite of next-generation weight-loss drugs from China's CSPC, aiming to challenge the dominance of Lilly and Novo Nordisk with longer-acting monthly injectables.
The AI-as-a-Service (AIaaS) market is witnessing significant growth, fueled by cloud innovation and corporate demand for scalable AI solutions. While data privacy remains a hurdle, the integration of generative AI and tailored platforms is accelerating adoption across industries.
Newly launched oral weight-loss drug Wegovy from Novo Nordisk recorded more than 26,000 U.S. prescriptions in its second full week, signaling robust early demand as competition with Eli Lilly intensifies.
While rising prices are felt at the checkout line, their long-term erosion of retirement savings is often overlooked. Experts warn that cumulative inflation across essential categories could create a six-figure shortfall for unprepared retirees.
The long-term strategic partnership will leverage IQVIA's data-as-a-service platform to unify and streamline commercial data across 59 countries, aiming to accelerate product launches and enhance decision-making for the pharmaceutical giant.
Israel announces the Rafah border crossing will reopen this Sunday for limited travel between Gaza and Egypt, marking a significant shift in access for the enclave's 2 million residents after an eight-month Israeli control of the vital gateway.
With major indices hovering near record levels and the Federal Reserve on hold, income-focused investors are turning to dividend payers for reliable returns. We analyze three standout stocks offering yields and stability as the market awaits tech earnings season.
IBM has launched a multi-billion dollar, multi-currency bond sale, becoming one of the first major technology firms to access debt markets this year. The move, which comes amid strong investor appetite for tech credit, is seen as a bellwether for how the sector will fund growth initiatives in artificial intelligence and strategic acquisitions.
Eli Lilly commits $85 million upfront and over $1.8 billion in potential milestones to partner with Repertoire Immune Medicines, aiming to develop a new class of 'tolerizing' therapies that reset the immune system without broad suppression.
The protective packaging leader's 2025 recycling achievement, driven by customer partnerships and its EmeraldPak product, marks a significant step in its 'Stairway to Green' initiative and underscores growing industry momentum for closed-loop systems.
Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.
